The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic Adenocarcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06553040

Enrollment

Registered

2024-08-14

Start date

2017-01-01

Completion date

2023-01-01

Last updated

2024-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Cancer, Pancreatic Neoplasms

Keywords

Pancreatic adenocancer, albumin, hemoglobin, lymphocyte, platelet

Brief summary

The aim of this study is to investigate whether the albumin value and the ratios of biochemical markers; hemoglobin, albumin, lymphocyte and platelet (HALP score) and lymphocyte-C-reactive protein ratio (LCR) can predict the survival and recurrence of the disease in patients with pancreatic adenocarcinoma.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Whipple operation and total pancreatectomy due to pathologically confirmed pancreatic adenocarcinoma

Exclusion criteria

* Patients with other malignant tumors (choledochal tumor, papilla tumor and duodenal tumor)

Design outcomes

Primary

Measure	Time frame	Description
Disease-Free Survival Times	4 Years	—
HALP Score	4 Years	Hemoglobin x Albumin x Lymphocyte / Platelet
Overall Survival Time	4 Years	—
LCR Score	4 Years	Lymphocyte / CRP

Outcome results